|Bid||17.87 x 100|
|Ask||26.68 x 2000|
|Day's Range||21.27 - 22.72|
|52 Week Range||21.27 - 43.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.25|
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
DUBLIN, April 19, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease (COPD). The IMPACT study is one of the largest trials ever conducted in COPD patients with a history of exacerbation.1 Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor ...
Theravance Biopharma Inc (NASDAQ:TBPH), a pharmaceuticals company based in Cayman Islands, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DUBLIN, March 21, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 9:00 a.m. ET. The conference will be held from March 27 - 28 at the Westin Grand Central Hotel in New York. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
The George Town, Cayman Islands-based company said it had a loss of $1.64 per share. The biopharmaceutical company posted revenue of $4.5 million in the period. For the year, the company reported that ...
Multiple Programs Poised to Advance in 2018 DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported ...
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Theravance Biopharma Inc NASDAQ: TBPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 5:00 PM Eastern ...
Don't be caught off-guard: Theravance Biopharma (NASDAQ: TBPH ) releases its next round of earnings Tuesday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018. An accompanying conference call will be held at 5:00 pm ET on February 27, 2018. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 3999284. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through March 29, 2018.
DUBLIN, Feb. 15, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
Stock Monitor: Enanta Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on Theravance Biopharma, Inc. (NASDAQ: TBPH ...
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.
DUBLIN, Feb. 7, 2018 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today announced that it has entered into a global co-development and commercialization agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Under the terms of the agreement, Theravance Biopharma will receive an upfront payment of $100 million and will be eligible to receive up to an additional $900 million in potential payments, if Janssen elects to remain in the collaboration following the completion of certain Phase 2 activities, as described below.
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.